Cullinan Therapeutics, Inc. (filed as Cullinan Oncology, Inc.) — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The company is a clinical-stage oncology biopharmaceutical developer with six clinical-stage candidates; it has no approved products and has not generated product-sales revenue.
Financial performance and position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $148.2 million | $91.9 million |
| General and administrative expense | $42.5 million | $40.2 million |
| Total operating expenses | $190.6 million | $132.1 million |
| Operating income (loss) | $(191.1) million | $144.6 million |
| Net income (loss) | $(155.1) million | $109.2 million |
| Net cash used in operating activities | $(134.3) million | $(126.7) million |
| Cash, cash equivalents, short-term investments and interest receivable | $468.3 million | — |
Liquidity and funding: Management expects current resources to fund operations into the second half of 2026, based on current plans and assumptions; it cautions that actual cash use could be faster. Current assets were $480.2 million and current liabilities $28.1 million at year-end. No material borrowings are reported on the balance sheet; total operating lease liabilities were $3.6 million. Cash and cash equivalents alone were $98.4 million, with $368.6 million in short-term investments.
Margins: Not meaningful for this pre-commercial company. The 2023 net loss included a $14.1 million income tax benefit and $21.6 million of interest income. The filing reports no 2023 product revenue.
Material changes versus 2022
- Net results swung from $109.2 million income in 2022 to a $155.1 million loss in 2023. The 2022 result included a $276.8 million gain on the sale of the zipalertinib subsidiary to Taiho; no comparable gain occurred in 2023.
- R&D expense rose $56.2 million, principally from higher clinical spending, the $25.0 million upfront CLN-418 license fee, and increased personnel costs. G&A expense increased $2.3 million.
- Operating cash use increased by $7.6 million. The 2023 financing inflow included $38.4 million net proceeds from an at-the-market stock offering; $85.6 million remained available under that program at year-end.
- Short-term investments increased to $368.6 million from $311.1 million, while long-term investments fell from $80.9 million to zero. Total cash, investments and interest receivable were $468.3 million at year-end.
Pipeline, outlook and notable items
- CLN-619: Phase 1 testing in advanced solid tumors, as monotherapy and with checkpoint inhibitors. Preliminary monotherapy results reported in 2023 included one complete response and two confirmed partial responses among 37 treated patients, with no dose-limiting toxicities reported. These are early, limited data. Management expected combination and updated monotherapy data in Q2 2024, expansion-cohort data in the first half of 2025, and the FDA cleared a multiple-myeloma trial application in February 2024.
- CLN-978: First patient dosed in a Phase 1 trial for relapsed/refractory B-cell non-Hodgkin lymphoma in August 2023. The company is also exploring autoimmune-disease development; this is not yet established clinical efficacy.
- Zipalertinib: Co-developed with Taiho; pivotal Phase 2b REZILIENT1 enrollment was expected to finish by year-end 2024. Taiho initiated the global Phase 3 REZILIENT3 trial in 2023. Development costs and potential U.S. pre-tax profits are shared equally, and Cullinan may receive up to $130 million in regulatory milestones from the prior asset sale; none had been achieved by year-end. Earlier Phase 1/2a results cited in the filing—41% confirmed response rate and median 12-month progression-free survival at 100 mg twice daily—are historical preliminary results, not the pivotal trial outcome.
- CLN-049 and CLN-418: Both were in Phase 1 trials; management expected updated CLN-049 data and initial CLN-418 data in the second half of 2024. CLN-049 also began a second Phase 1 trial in minimal residual disease-positive AML in December 2023.
- CLN-617: First patient dosed in a Phase 1 trial in December 2023.
- Management says it applies go/no-go criteria, may discontinue programs that do not meet its development thresholds, and balances pipeline investment with maintaining cash runway. The company expects continued operating losses and no near-term product-sales revenue.
- CLN-418 was licensed from Harbour for $25 million upfront, with up to $148 million in development and regulatory milestones, up to $415 million in sales milestones and tiered royalties. Other license and collaboration agreements also provide for contingent milestones and royalties; amounts are generally dependent on future events.
- A $0.4 million long-lived-asset impairment was recorded in 2023 after cancellation of a sublease. No material litigation was reported. The auditor issued an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective, though the auditor was not required to attest to internal controls.
- After year-end, the company announced CFO Jeffrey Trigilio’s departure effective March 29, 2024, and appointed Nate Nguyen interim principal financial and accounting officer. The filing also describes severance, consulting and equity-vesting terms for the departing CFO.
Key risks and investor verification points
- Verify the latest clinical-trial data, patient numbers, follow-up, safety findings and trial status; early and interim results may change and may not predict later outcomes.
- Assess whether the projected cash runway remains achievable as trial costs rise, and whether further financing, dilution or program reductions may be needed. The company had 647,500 preferred shares outstanding at year-end, convertible into common shares subject to ownership limits, as well as substantial outstanding equity awards.
- Track zipalertinib’s pivotal Phase 2b and Phase 3 progress, competitive landscape and milestone conditions; the company shares U.S. development costs and potential profits equally with Taiho.
- Consider clinical, regulatory, patient-enrollment, safety, reimbursement, patent and competition risks across a pipeline that remains early-stage. The company relies heavily on third-party research, trial and manufacturing providers, including some single-source supply arrangements.
- Review contingent license payments, royalties and subsidiary-level investor or licensor rights that could affect future economics or transactions. Also verify the CFO transition and subsequent filings regarding its final terms.